SCHEMBL21158895

SCHEMBL21158895

CN(C)CC(C(=O)N1C2CC1CN(C(C)(C)C)C2)c1ccc(F)cc1

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
RET P07949 3/20 0.45
DPP4 P27487 8/20 0.39
DPP7 Q9UHL4 7/20 0.39
DPP8 Q6V1X1 3/20 0.39
KCNH2 Q12809 4/20 0.35
SLC6A3 Q01959 2/20 0.35
MC4R P32245 1/20 0.35
DPP9 Q86TI2 3/20 0.34
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C19 P33261 1/20 0.33
CHRM1 P11229 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20069728 0.87 RET (0.48) RETDPP4DPP7DPP8KCNH2
SCHEMBL20152348 0.85 RET (0.45) RETDPP4DPP7DPP8KCNH2
SCHEMBL22030577 0.85 RET (0.47) RETDPP4DPP7DPP8KCNH2
SCHEMBL22812245 0.82 RET (0.43) RETDPP4DPP7DPP8KCNH2
SCHEMBL23126260 0.82 RET (0.43) RETDPP4DPP7DPP8KCNH2
SCHEMBL21158897 0.81 RET (0.40) RETDPP4DPP7DPP8KCNH2
SCHEMBL21158898 0.80 RET (0.42) RETDPP4DPP7DPP8KCNH2
SCHEMBL20148611 0.74 RET (0.37) RETDPP4DPP7DPP8SLC6A3
SCHEMBL20154582 0.72 RET (0.47) RETDPP4DPP7DPP8KCNH2
SCHEMBL20069729 0.71 RET (0.46) RETDPP4DPP7DPP8KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10953005-B1 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2021-03-23 US disclosed
US-10555944-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ELI LILLY AND COMPANY (US) 2020-02-11 US disclosed
US-20190183886-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2019-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10555944-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, ROR1, BRAF RET 1/4885DPP4 1948/4885DPP7 2391/4885
US-10953005-B1 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors RET, ROR1, BRAF RET 1/4885DPP4 1948/4885DPP7 2391/4885
US-20190183886-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF RET 1/4885DPP4 1948/4885DPP7 2391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.